Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: Syndax Pharmaceuticals Inc., 3 years.
Chief executive roles
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 35% of the scoring weight is on file.
- Revenue growth 20%
- 100
- Earnings growth 15%
- 100
21.2% a year in revenue
1,000% a year in earnings per share
35% of the scoring weight is on file. Figures cover December 2024 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Syndax Pharmaceuticals Inc. May 14, 202486.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 16, 2026 | Incyte Corp. | Grant or award | +26,807 | — | — |
| Jul 2, 2026 | Incyte Corp. | Shares withheld for tax | −4,779 | $116.86 | $558,474 |
| Apr 15, 2026 | Incyte Corp. | Option exercise | +125,000 | — | — |
| Jul 2, 2025 | Incyte Corp. | Grant or award | +36,101 | — | — |
| Feb 5, 2025 | Syndax Pharmaceuticals Inc. | Grant or award | +25,000 | — | — |
| Feb 7, 2024 | Syndax Pharmaceuticals Inc. | Grant or award | +17,000 | — | — |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Option exercise | +35,000 | $7.11 | $248,850 |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Open-market sale | −35,000 | $20.46 | $716,100 |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Option exercise | +24,000 | $7.88 | $189,120 |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Open-market sale | −24,000 | $20.46 | $491,040 |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Option exercise | +24,000 | $9.47 | $227,280 |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Open-market sale | −24,000 | $20.45 | $490,800 |
| Feb 2, 2023 | Syndax Pharmaceuticals Inc. | Grant or award | +16,000 | — | — |
Questions about William Meury
What boards is William Meury on?
William Meury sits on the boards of Incyte Corp. and Syndax Pharmaceuticals Inc.
What company is William Meury the CEO of?
William Meury has been Chief Executive Officer of Incyte Corp. since June 2025.
How long has William Meury served on boards?
Our records show at least 5 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.